SrasV1, PubMed, Curation, bibRecord, 002744

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Identifieur interne : 002744 ( PubMed/Curation ); précédent : 002743; suivant : 002745

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Auteurs : Lili Chen ; Chunshan Gui ; Xiaomin Luo ; Qingang Yang ; Stephan Günther ; Elke Scandella ; Christian Drosten ; Donglu Bai ; Xichang He ; Burkhard Ludewig ; Jing Chen ; Haibin Luo ; Yiming Yang ; Yifu Yang ; Jianping Zou ; Volker Thiel ; Kaixian Chen ; Jianhua Shen ; Xu Shen ; Hualiang Jiang

Source :

Journal of virology [ 0022-538X ] ; 2005.

RBID : pubmed:15890949

Descripteurs français

KwdFr :
- ADN viral (génétique), Animaux, Antiviraux (), Antiviraux (pharmacologie), Cellules Vero, Cinansérine (), Cinansérine (pharmacologie), Cricetinae, Cysteine endopeptidases, Endopeptidases (), Endopeptidases (génétique), Humains, Inhibiteurs de protéases (), Inhibiteurs de protéases (pharmacologie), Interface utilisateur, Lignée cellulaire, Modèles moléculaires, Protéines recombinantes (antagonistes et inhibiteurs), Protéines recombinantes (génétique), Protéines virales (), Protéines virales (antagonistes et inhibiteurs), Protéines virales (génétique), RNA replicase (antagonistes et inhibiteurs), Réplication virale (), Séquence nucléotidique, Techniques in vitro, Virus du SRAS (), Virus du SRAS (enzymologie), Virus du SRAS (génétique), Virus du SRAS (physiologie), Évaluation préclinique de médicament ().
MESH :
- antagonistes et inhibiteurs : Protéines recombinantes, Protéines virales, RNA replicase.
- enzymologie : Virus du SRAS.
- génétique : ADN viral, Endopeptidases, Protéines recombinantes, Protéines virales, Virus du SRAS.
- pharmacologie : Antiviraux, Cinansérine, Inhibiteurs de protéases.
- physiologie : Virus du SRAS.
- Animaux, Antiviraux, Cellules Vero, Cinansérine, Cricetinae, Cysteine endopeptidases, Endopeptidases, Humains, Inhibiteurs de protéases, Interface utilisateur, Lignée cellulaire, Modèles moléculaires, Protéines virales, Réplication virale, Séquence nucléotidique, Techniques in vitro, Virus du SRAS, Évaluation préclinique de médicament.

English descriptors

KwdEn :
- Animals, Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Base Sequence, Cell Line, Chlorocebus aethiops, Cinanserin (chemistry), Cinanserin (pharmacology), Cricetinae, Cysteine Endopeptidases, DNA, Viral (genetics), Drug Evaluation, Preclinical (methods), Endopeptidases (chemistry), Endopeptidases (genetics), Humans, In Vitro Techniques, Models, Molecular, Protease Inhibitors (chemistry), Protease Inhibitors (pharmacology), RNA Replicase (antagonists & inhibitors), Recombinant Proteins (antagonists & inhibitors), Recombinant Proteins (genetics), SARS Virus (drug effects), SARS Virus (enzymology), SARS Virus (genetics), SARS Virus (physiology), User-Computer Interface, Vero Cells, Viral Proteins (antagonists & inhibitors), Viral Proteins (chemistry), Viral Proteins (genetics), Virus Replication (drug effects).
MESH :
- chemical , antagonists & inhibitors : RNA Replicase, Recombinant Proteins, Viral Proteins.
- chemical , chemistry : Antiviral Agents, Cinanserin, Endopeptidases, Protease Inhibitors, Viral Proteins.
- chemical , genetics : DNA, Viral, Endopeptidases, Recombinant Proteins, Viral Proteins.
- chemical , pharmacology : Antiviral Agents, Cinanserin, Protease Inhibitors.
- drug effects : SARS Virus, Virus Replication.
- enzymology : SARS Virus.
- genetics : SARS Virus.
- methods : Drug Evaluation, Preclinical.
- physiology : SARS Virus.
- Animals, Base Sequence, Cell Line, Chlorocebus aethiops, Cricetinae, Cysteine Endopeptidases, Humans, In Vitro Techniques, Models, Molecular, User-Computer Interface, Vero Cells.

Abstract

The 3C-like proteinase (3CLpro) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is one of the most promising targets for anti-SARS-CoV drugs due to its crucial role in the viral life cycle. In this study, a database containing structural information of more than 8,000 existing drugs was virtually screened by a docking approach to identify potential binding molecules of SARS-CoV 3CLpro. As a target for screening, both a homology model and the crystallographic structure of the binding pocket of the enzyme were used. Cinanserin (SQ 10,643), a well-characterized serotonin antagonist that has undergone preliminary clinical testing in humans in the 1960s, showed a high score in the screening and was chosen for further experimental evaluation. Binding of both cinanserin and its hydrochloride to bacterially expressed 3CLpro of SARS-CoV and the related human coronavirus 229E (HCoV-229E) was demonstrated by surface plasmon resonance technology. The catalytic activity of both enzymes was inhibited with 50% inhibitory concentration (IC50) values of 5 microM, as tested with a fluorogenic substrate. The antiviral activity of cinanserin was further evaluated in tissue culture assays, namely, a replicon system based on HCoV-229E and quantitative test assays with infectious SARS-CoV and HCoV-229E. All assays revealed a strong inhibition of coronavirus replication at nontoxic drug concentrations. The level of virus RNA and infectious particles was reduced by up to 4 log units, with IC50 values ranging from 19 to 34 microM. These findings demonstrate that the old drug cinanserin is an inhibitor of SARS-CoV replication, acting most likely via inhibition of the 3CL proteinase.

DOI: 10.1128/JVI.79.11.7095-7103.2005
PubMed: 15890949

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002744

Links to Exploration step

pubmed:15890949

Curation

No country items

Lili Chen

<affiliation><nlm:affiliation>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.</nlm:affiliation>
<wicri:noCountry code="subField">Chinese Academy of Sciences</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.</title>
<author><name sortKey="Chen, Lili" sort="Chen, Lili" uniqKey="Chen L" first="Lili" last="Chen">Lili Chen</name>
<affiliation><nlm:affiliation>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.</nlm:affiliation>
<wicri:noCountry code="subField">Chinese Academy of Sciences</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gui, Chunshan" sort="Gui, Chunshan" uniqKey="Gui C" first="Chunshan" last="Gui">Chunshan Gui</name>
</author>
<author><name sortKey="Luo, Xiaomin" sort="Luo, Xiaomin" uniqKey="Luo X" first="Xiaomin" last="Luo">Xiaomin Luo</name>
</author>
<author><name sortKey="Yang, Qingang" sort="Yang, Qingang" uniqKey="Yang Q" first="Qingang" last="Yang">Qingang Yang</name>
</author>
<author><name sortKey="Gunther, Stephan" sort="Gunther, Stephan" uniqKey="Gunther S" first="Stephan" last="Günther">Stephan Günther</name>
</author>
<author><name sortKey="Scandella, Elke" sort="Scandella, Elke" uniqKey="Scandella E" first="Elke" last="Scandella">Elke Scandella</name>
</author>
<author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name>
</author>
<author><name sortKey="Bai, Donglu" sort="Bai, Donglu" uniqKey="Bai D" first="Donglu" last="Bai">Donglu Bai</name>
</author>
<author><name sortKey="He, Xichang" sort="He, Xichang" uniqKey="He X" first="Xichang" last="He">Xichang He</name>
</author>
<author><name sortKey="Ludewig, Burkhard" sort="Ludewig, Burkhard" uniqKey="Ludewig B" first="Burkhard" last="Ludewig">Burkhard Ludewig</name>
</author>
<author><name sortKey="Chen, Jing" sort="Chen, Jing" uniqKey="Chen J" first="Jing" last="Chen">Jing Chen</name>
</author>
<author><name sortKey="Luo, Haibin" sort="Luo, Haibin" uniqKey="Luo H" first="Haibin" last="Luo">Haibin Luo</name>
</author>
<author><name sortKey="Yang, Yiming" sort="Yang, Yiming" uniqKey="Yang Y" first="Yiming" last="Yang">Yiming Yang</name>
</author>
<author><name sortKey="Yang, Yifu" sort="Yang, Yifu" uniqKey="Yang Y" first="Yifu" last="Yang">Yifu Yang</name>
</author>
<author><name sortKey="Zou, Jianping" sort="Zou, Jianping" uniqKey="Zou J" first="Jianping" last="Zou">Jianping Zou</name>
</author>
<author><name sortKey="Thiel, Volker" sort="Thiel, Volker" uniqKey="Thiel V" first="Volker" last="Thiel">Volker Thiel</name>
</author>
<author><name sortKey="Chen, Kaixian" sort="Chen, Kaixian" uniqKey="Chen K" first="Kaixian" last="Chen">Kaixian Chen</name>
</author>
<author><name sortKey="Shen, Jianhua" sort="Shen, Jianhua" uniqKey="Shen J" first="Jianhua" last="Shen">Jianhua Shen</name>
</author>
<author><name sortKey="Shen, Xu" sort="Shen, Xu" uniqKey="Shen X" first="Xu" last="Shen">Xu Shen</name>
</author>
<author><name sortKey="Jiang, Hualiang" sort="Jiang, Hualiang" uniqKey="Jiang H" first="Hualiang" last="Jiang">Hualiang Jiang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15890949</idno>
<idno type="pmid">15890949</idno>
<idno type="doi">10.1128/JVI.79.11.7095-7103.2005</idno>
<idno type="wicri:Area/PubMed/Corpus">002744</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002744</idno>
<idno type="wicri:Area/PubMed/Curation">002744</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002744</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.</title>
<author><name sortKey="Chen, Lili" sort="Chen, Lili" uniqKey="Chen L" first="Lili" last="Chen">Lili Chen</name>
<affiliation><nlm:affiliation>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.</nlm:affiliation>
<wicri:noCountry code="subField">Chinese Academy of Sciences</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gui, Chunshan" sort="Gui, Chunshan" uniqKey="Gui C" first="Chunshan" last="Gui">Chunshan Gui</name>
</author>
<author><name sortKey="Luo, Xiaomin" sort="Luo, Xiaomin" uniqKey="Luo X" first="Xiaomin" last="Luo">Xiaomin Luo</name>
</author>
<author><name sortKey="Yang, Qingang" sort="Yang, Qingang" uniqKey="Yang Q" first="Qingang" last="Yang">Qingang Yang</name>
</author>
<author><name sortKey="Gunther, Stephan" sort="Gunther, Stephan" uniqKey="Gunther S" first="Stephan" last="Günther">Stephan Günther</name>
</author>
<author><name sortKey="Scandella, Elke" sort="Scandella, Elke" uniqKey="Scandella E" first="Elke" last="Scandella">Elke Scandella</name>
</author>
<author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name>
</author>
<author><name sortKey="Bai, Donglu" sort="Bai, Donglu" uniqKey="Bai D" first="Donglu" last="Bai">Donglu Bai</name>
</author>
<author><name sortKey="He, Xichang" sort="He, Xichang" uniqKey="He X" first="Xichang" last="He">Xichang He</name>
</author>
<author><name sortKey="Ludewig, Burkhard" sort="Ludewig, Burkhard" uniqKey="Ludewig B" first="Burkhard" last="Ludewig">Burkhard Ludewig</name>
</author>
<author><name sortKey="Chen, Jing" sort="Chen, Jing" uniqKey="Chen J" first="Jing" last="Chen">Jing Chen</name>
</author>
<author><name sortKey="Luo, Haibin" sort="Luo, Haibin" uniqKey="Luo H" first="Haibin" last="Luo">Haibin Luo</name>
</author>
<author><name sortKey="Yang, Yiming" sort="Yang, Yiming" uniqKey="Yang Y" first="Yiming" last="Yang">Yiming Yang</name>
</author>
<author><name sortKey="Yang, Yifu" sort="Yang, Yifu" uniqKey="Yang Y" first="Yifu" last="Yang">Yifu Yang</name>
</author>
<author><name sortKey="Zou, Jianping" sort="Zou, Jianping" uniqKey="Zou J" first="Jianping" last="Zou">Jianping Zou</name>
</author>
<author><name sortKey="Thiel, Volker" sort="Thiel, Volker" uniqKey="Thiel V" first="Volker" last="Thiel">Volker Thiel</name>
</author>
<author><name sortKey="Chen, Kaixian" sort="Chen, Kaixian" uniqKey="Chen K" first="Kaixian" last="Chen">Kaixian Chen</name>
</author>
<author><name sortKey="Shen, Jianhua" sort="Shen, Jianhua" uniqKey="Shen J" first="Jianhua" last="Shen">Jianhua Shen</name>
</author>
<author><name sortKey="Shen, Xu" sort="Shen, Xu" uniqKey="Shen X" first="Xu" last="Shen">Xu Shen</name>
</author>
<author><name sortKey="Jiang, Hualiang" sort="Jiang, Hualiang" uniqKey="Jiang H" first="Hualiang" last="Jiang">Hualiang Jiang</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Base Sequence</term>
<term>Cell Line</term>
<term>Chlorocebus aethiops</term>
<term>Cinanserin (chemistry)</term>
<term>Cinanserin (pharmacology)</term>
<term>Cricetinae</term>
<term>Cysteine Endopeptidases</term>
<term>DNA, Viral (genetics)</term>
<term>Drug Evaluation, Preclinical (methods)</term>
<term>Endopeptidases (chemistry)</term>
<term>Endopeptidases (genetics)</term>
<term>Humans</term>
<term>In Vitro Techniques</term>
<term>Models, Molecular</term>
<term>Protease Inhibitors (chemistry)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>RNA Replicase (antagonists & inhibitors)</term>
<term>Recombinant Proteins (antagonists & inhibitors)</term>
<term>Recombinant Proteins (genetics)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (enzymology)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (physiology)</term>
<term>User-Computer Interface</term>
<term>Vero Cells</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
<term>Viral Proteins (chemistry)</term>
<term>Viral Proteins (genetics)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (génétique)</term>
<term>Animaux</term>
<term>Antiviraux ()</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Cinansérine ()</term>
<term>Cinansérine (pharmacologie)</term>
<term>Cricetinae</term>
<term>Cysteine endopeptidases</term>
<term>Endopeptidases ()</term>
<term>Endopeptidases (génétique)</term>
<term>Humains</term>
<term>Inhibiteurs de protéases ()</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Interface utilisateur</term>
<term>Lignée cellulaire</term>
<term>Modèles moléculaires</term>
<term>Protéines recombinantes (antagonistes et inhibiteurs)</term>
<term>Protéines recombinantes (génétique)</term>
<term>Protéines virales ()</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>Protéines virales (génétique)</term>
<term>RNA replicase (antagonistes et inhibiteurs)</term>
<term>Réplication virale ()</term>
<term>Séquence nucléotidique</term>
<term>Techniques in vitro</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (enzymologie)</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (physiologie)</term>
<term>Évaluation préclinique de médicament ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA Replicase</term>
<term>Recombinant Proteins</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term>
<term>Cinanserin</term>
<term>Endopeptidases</term>
<term>Protease Inhibitors</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>DNA, Viral</term>
<term>Endopeptidases</term>
<term>Recombinant Proteins</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Cinanserin</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines recombinantes</term>
<term>Protéines virales</term>
<term>RNA replicase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ADN viral</term>
<term>Endopeptidases</term>
<term>Protéines recombinantes</term>
<term>Protéines virales</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Cinansérine</term>
<term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Base Sequence</term>
<term>Cell Line</term>
<term>Chlorocebus aethiops</term>
<term>Cricetinae</term>
<term>Cysteine Endopeptidases</term>
<term>Humans</term>
<term>In Vitro Techniques</term>
<term>Models, Molecular</term>
<term>User-Computer Interface</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux</term>
<term>Cellules Vero</term>
<term>Cinansérine</term>
<term>Cricetinae</term>
<term>Cysteine endopeptidases</term>
<term>Endopeptidases</term>
<term>Humains</term>
<term>Inhibiteurs de protéases</term>
<term>Interface utilisateur</term>
<term>Lignée cellulaire</term>
<term>Modèles moléculaires</term>
<term>Protéines virales</term>
<term>Réplication virale</term>
<term>Séquence nucléotidique</term>
<term>Techniques in vitro</term>
<term>Virus du SRAS</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The 3C-like proteinase (3CLpro) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is one of the most promising targets for anti-SARS-CoV drugs due to its crucial role in the viral life cycle. In this study, a database containing structural information of more than 8,000 existing drugs was virtually screened by a docking approach to identify potential binding molecules of SARS-CoV 3CLpro. As a target for screening, both a homology model and the crystallographic structure of the binding pocket of the enzyme were used. Cinanserin (SQ 10,643), a well-characterized serotonin antagonist that has undergone preliminary clinical testing in humans in the 1960s, showed a high score in the screening and was chosen for further experimental evaluation. Binding of both cinanserin and its hydrochloride to bacterially expressed 3CLpro of SARS-CoV and the related human coronavirus 229E (HCoV-229E) was demonstrated by surface plasmon resonance technology. The catalytic activity of both enzymes was inhibited with 50% inhibitory concentration (IC50) values of 5 microM, as tested with a fluorogenic substrate. The antiviral activity of cinanserin was further evaluated in tissue culture assays, namely, a replicon system based on HCoV-229E and quantitative test assays with infectious SARS-CoV and HCoV-229E. All assays revealed a strong inhibition of coronavirus replication at nontoxic drug concentrations. The level of virus RNA and infectious particles was reduced by up to 4 log units, with IC50 values ranging from 19 to 34 microM. These findings demonstrate that the old drug cinanserin is an inhibitor of SARS-CoV replication, acting most likely via inhibition of the 3CL proteinase.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15890949</PMID>
<DateCompleted><Year>2005</Year>
<Month>06</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>79</Volume>
<Issue>11</Issue>
<PubDate><Year>2005</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.</ArticleTitle>
<Pagination><MedlinePgn>7095-103</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The 3C-like proteinase (3CLpro) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is one of the most promising targets for anti-SARS-CoV drugs due to its crucial role in the viral life cycle. In this study, a database containing structural information of more than 8,000 existing drugs was virtually screened by a docking approach to identify potential binding molecules of SARS-CoV 3CLpro. As a target for screening, both a homology model and the crystallographic structure of the binding pocket of the enzyme were used. Cinanserin (SQ 10,643), a well-characterized serotonin antagonist that has undergone preliminary clinical testing in humans in the 1960s, showed a high score in the screening and was chosen for further experimental evaluation. Binding of both cinanserin and its hydrochloride to bacterially expressed 3CLpro of SARS-CoV and the related human coronavirus 229E (HCoV-229E) was demonstrated by surface plasmon resonance technology. The catalytic activity of both enzymes was inhibited with 50% inhibitory concentration (IC50) values of 5 microM, as tested with a fluorogenic substrate. The antiviral activity of cinanserin was further evaluated in tissue culture assays, namely, a replicon system based on HCoV-229E and quantitative test assays with infectious SARS-CoV and HCoV-229E. All assays revealed a strong inhibition of coronavirus replication at nontoxic drug concentrations. The level of virus RNA and infectious particles was reduced by up to 4 log units, with IC50 values ranging from 19 to 34 microM. These findings demonstrate that the old drug cinanserin is an inhibitor of SARS-CoV replication, acting most likely via inhibition of the 3CL proteinase.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Lili</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gui</LastName>
<ForeName>Chunshan</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Luo</LastName>
<ForeName>Xiaomin</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Qingang</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y"><LastName>Günther</LastName>
<ForeName>Stephan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Scandella</LastName>
<ForeName>Elke</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Drosten</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bai</LastName>
<ForeName>Donglu</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Xichang</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ludewig</LastName>
<ForeName>Burkhard</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Luo</LastName>
<ForeName>Haibin</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Yiming</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Yifu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zou</LastName>
<ForeName>Jianping</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Thiel</LastName>
<ForeName>Volker</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Kaixian</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>Jianhua</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>Xu</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Hualiang</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber>
<NameOfSubstance UI="D012324">RNA Replicase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>KI6J9OY7A3</RegistryNumber>
<NameOfSubstance UI="D002928">Cinanserin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002928" MajorTopicYN="N">Cinanserin</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA Replicase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014584" MajorTopicYN="N">User-Computer Interface</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15890949</ArticleId>
<ArticleId IdType="pii">79/11/7095</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.79.11.7095-7103.2005</ArticleId>
<ArticleId IdType="pmc">PMC1112131</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5619-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 11;318(4):862-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15147951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2004 Jun;85(Pt 6):1717-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15166457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12694-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15304651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2004 Sep;63(3):209-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15451189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Int Pharmacodyn Ther. 1965 May;155(1):225-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5834938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 1968 Jun;121(6):507-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4870935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Ther Res Clin Exp. 1968 Sep;10(9):461-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4971651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Psychiatry. 1970 Jan;126(7):1020-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5409554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dis Nerv Syst. 1971 Mar;32(3):193-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4929084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Surg Forum. 1970;21:254-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4936978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Surg Forum. 1970;21:287-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4936985</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Surg Oncol. 1970;2(2):145-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4939050</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Pharmacol Sin. 2003 Jun;24(6):497-504</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12791174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2000 Apr;81(Pt 4):853-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10725411</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Graph Model. 2002 Jan;20(4):281-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11858637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Chem Biol. 2002 Aug;6(4):439-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12133718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2004 May 1;12(9):2219-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15080921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6212-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15073334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2003 Oct 23;553(3):451-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14572668</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Oct 30;425(6961):915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14586458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2003 Nov 17;13(22):3989-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Structure. 2004 Feb;12(2):341-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14962394</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Expr Purif. 2003 Dec;32(2):302-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14965777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3792-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15007178</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2004;10(9):1011-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharmacol New Drugs. 1971 May-Jun;11(3):220-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4946100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1990 Mar;28(3):495-503</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1691208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 1992 Oct 16;35(21):3727-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1433187</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Biochem Biophys. 1997 Oct 1;346(1):125-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9328292</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Int Pharmacodyn Ther. 1964 Nov 1;152:132-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14248340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Soc Exp Biol Med. 1965 Jun;119:438-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14328912</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Jan;79(2):884-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15613317</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002744 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002744 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15890949
   |texte=   Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:15890949" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki